Authors: Xiangjun Fu, Li’e Lin, Hongxia Yao, Li Huang, Can Meng, Shuwen Wang,
Dan Liu, Li Guo, Mengling Duan
ABSTRACT
Rituximab is a mouse and human chimeric CD20 (anti-B cell) specific monoclonal antibody that has been approved by the U.S. Food and Drug Administration for the treatment of lymphoma. The expression of 20 antigen is expressed in the whole ontogeny of B cells, starting from the premature B cells in bone marrow to the differentiation of plasma cells in secondary lymphoid tissues. The wide distribution of 20 molecules allows rituximab to eliminate a large number of B cells. Rituximab is the core drug for the treatment of hematological diseases, often combined with drugs as a first-line treatment. Long-term hormone therapy often results in serious adverse reactions, and new therapies, which can avoid widespread immunotoxicity, have great potential for treating diseases of the blood system.
Source:
Journal： Open Journal of Blood Diseases
DOI: 10.4236/ojbd.2021.111002(PDF)
Paper Id: 107540 (metadata)
See also: Comments to Paper